

DAFTAR PUSTAKA

1. Kumar A, Palfrey HA, Pathak R, Kadowitz PJ, Gettys TW, Murthy SN. The metabolism and significance of homocysteine in nutrition and health. *Nutr Metab (Lond)*. 2017;14:78.
2. Skovierova H, Vidomanova E, Mahmood S, Sopkova J, Drgova A, Cernenovs T et al. The molecular and cellular effect of homocysteine metabolism imbalance on human health. *Int J Mol Sci*. 2016;17:1733.
3. Mutairi FA. Hyperhomocysteinemia: Clinical Insights. *Journal of Central Nervous System Disease*. 2020;12:1–8
4. Kim J, Kim H, Roh H, Kwon Y. Causes of hyperhomocysteinemia and its pathological significance. *Arch Pharm Res*. 2018;41:372–83.
5. Pinzon IT, Wijaya BM, Pramudita EA, Wuryaningsih NS, Sujatno P. Prevalence of elevated levels of homocysteine (hyperhomocysteinemia) in patients with chronic kidney disease undergoing hemodialysis. *J Clin Med Kazakhstan*. 2019;3(53):21–5.
6. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. *Kidney Int Suppl*. 2022;12(1):7–11.
7. Riset Kesehatan Dasar (Riskesdas). Badan penelitian dan pengembangan kesehatan kementerian RI. 2018.
8. M. Djamil. 10 Penyakit terbanyak terbanyak penyakit dalam RSUP Dr. M. Djamil Padang. 2020.

9. Ye Z, Wang C, Zhang Q, Li Y, Zhang J, Ma X et al. Prevalence of homocysteine-related hypertension in patients with chronic kidney disease. *J Clin Hypertens*. 2017;19(2):151–60.
10. Liu T, Lin J, Ju T, Chu L, Zhang L. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves matrix metalloproteinase-2 modulation by homocysteine. *Mol Cell Biochem*. 2015; 406(1-2): 139–49.
11. Chen CH, Yeh EL, Chen CC, Huang SC, Huang YC. Vitamin B-6, independent of homocysteine, is a significant factor in relation to inflammatory responses for chronic kidney disease and hemodialysis patients. *BioMed Research International*. 2017:1–8.
12. Ye Z, Zhang Q, Li Y, Wang C, Zhang J, Ma X, et al. High prevalence of hyperhomocysteinemia and its association with target organ damage in chinese patients with chronic kidney disease. *Nutrients* 2016; 8(10):645.
13. Olokor A, Ojogwu I, Ugbodaga P. Hyperhomocysteinemia in chronic kidney disease patients in a teaching hospital in Nigeria. *Br J Med Med Res*. 2016;18(9):1–7.
14. Markisic M, Pavlovic AM, Pavlovic DM. The impact of homocysteine, vitamin B12, and vitamin D levels on functional outcome after first-ever ischaemic stroke. *Biomed Res Int*. 2017
15. Liu M, Li XC, Lu L, Cao Y, Sun R, Chen S et al. Cardiovascular disease and its relationship with chronic kidney disease. *European review for medical and pharmacological sciences*. 2014;18:2816–26
16. Amaliah R, Yaswir R, Prihandani T. Gambaran homosistein pada pasien infark miokard akut di RSUP Dr. M. Djamil Padang. *JKA*. 2019;8(2):351–5

17. Badri S, Vahdat S, Seirafian S, Pourfarzam M, Shahraki TG, Ataei S. Homocysteine-lowering interventions in chronic kidney disease. *J Res Pharm Pract* 2021;10:114–24.
18. Cianciolo G, De Pascalis A, Di Lullo L, Ronco C, Zannini C, La Manna G. Folic acid and homocysteine in chronic kidney disease and cardiovascular disease progression: which comes first. *Cardiorenal Med.* 2017;7(4):255–66.
19. Perna AF, Ingrosso D. Homocysteine and chronic kidney disease: an ongoing narrative. *J Nephrol.* 2019;32(5):673–5.
20. Wang M, Guo Y, Zhao W. Gastrointestinal disorders in chronic kidney disease. *Longhua Chin Med.* 2019;2:1–4.
21. Kosmadakis G, Da Costa Correia E, Carceles O, Somda F, Aguilera D. Vitamins in dialysis: who, when and how much? *Ren Fail.* 2014;36(4):638–50.
22. Juszczak AB, Kupczak M, Konecki T. Does vitamin supplementation play a role in chronic kidney disease? *Nutrients.* 2023;15(13):2847.
23. Gonzalez GO, Inzitari M, Belleli G, Morandi A, Barcons N, Vina J. Impact of supplementation with vitamins B6, B12, and/or folic acid on the reduction of homocysteine levels in patients with mild cognitive impairment: A systematic review. *IUMB Life.* 2022;74:74–84.
24. Frick B, Gruber B, Schroecksadel K, Leblhuber F, Fuchs D. Homocysteine but not neopterin declines in demented patients on B vitamins. *J Neural Transm.* 2006;113(11):1815–9.
25. Sansayi RD, Pinzon RT, Pramudita EA. Manfaat pemberian vitamin b kombinasi untuk menurunkan kadar homosistein pada gagal ginjal kronis. *Callosum Neurlogi.* 2019.

26. Pinzon RT, Sansayi RD, Pramudita EA. The proportion hyperhomocysteinemia in chronic kidney disease patients. *Asian jour med sciences*.2020;11:14–7.
27. Gilman AG, Hardman JG, Limbird LE. *Dasar farmakologi terapi*. 10th Ed. Jakarta; EGC. 2014
28. Vondracek SF, Teitelbaum I, Kiser TH. Principles of kidney pharmacotherapy for the nephrologist: core curriculum 2021. *AJDK*. 2021;78(3).
29. International Society of Nephrology. *KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease*. 2012.
30. Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. *Kidney Int*. 2020;97(6):1117–29.
31. Yan Y, Wang M, Zee J, Schaubel D, Tu C, Qian J et al. Twice-weekly hemodialysis and clinical outcomes in the china dialysis outcomes and practice patterns study. *Kidney Int Rep*. 2018;3(4):889–96.
32. Tinelli C, Di Pino A, Ficulle E, Marcelli S, Feligioni M. Hyperhomocysteinemia as a risk factor and potential nutraceutical target for certain pathologies. *Front Nutr*. 2019;6:49.
33. Angelini A, Cappuccilli ML, Magnoni G, Chicchini AL, Aiello V, Napoletano A. The link between homocysteine, folic acid and vitamin B12 in chronic kidney disease. *G Ital Nefrol*. 2020;4.
34. Stirzaker C, Song JZ, Ng W, Du Q, Armstrong NJ, Locke WJ et al. Methyl-CpG-binding protein MBD2 plays a key role in maintenance and spread of

- DNA methylation at CpG islands and shores in cancer. *Oncogene*. 2017;36:1328–38.
35. Ambrosino P, Lupoli R, Di Minno A, Nardo A, Marrone E, Lupoli V et al. Cyclic supplementation of 5-MTHF is effective for the correction of hyperhomocysteinemia. *Nutr Res*. 2015;35: 489–95.
36. Yakub M, Moti N, Parveen S, Chaudhry B, Azam I, Iqbal MP. Polymorphisms in MTHFR, MS and CBS genes and homocysteine levels in a pakistani population. Roca AL, ed. *PLoS ONE*. 2012;7(3)
37. Arina CA, Amir D, Siregar Y, Sembiring RJ. The role of polymorphism gen methylene tetra hydrofolate reductase (MTHFR) C677T in ischaemic stroke patients with and without hypertension. *Open Access Maced J Med Sci*. 2019;7:29–32.
38. Barić I, Staufner C, Augoustides-Savvopoulou P, Chien YH, Dobbelaere D, Grünert SC et al. Consensus recommendations for the diagnosis, treatment and follow-up of inherited methylation disorders. *J Inherit Metab Dis*. 2017;40(1):5–20.
39. Fu Y, Wang X, Kong W. Hyperhomocysteinemia and vascular injury: advances in mechanisms and drug targets. *Br J Pharmacol*. 2018;175:1173–89.
40. Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. *Nutr J*. 2015;14(1):6.
41. Alsolami AA, Almaiki AA, Alhedya SY, Alghamdi A, Alzahrani SM, Dause WR et al. Plasma homocysteine levels and cardiovascular events in patients with end-stage renal disease; a systematic review. *Cureus*. 2023;15(6)

42. Huang S, Cai J, Tian Y. The prognostic value of homocysteine in acute ischemic stroke patients: a systematic review and meta-analysis. *Front Syst Neurosci.* 2021;14.
43. Holmen M, Hvas AM, Arendt JFH. Hyperhomocysteinemia and ischemic stroke: a potential dose-response association—a systematic review and meta-analysis. *TH Open.* 2021;05(03):420–37.
44. Suwanto D. Peran Hiperhomosisteinemia dalam Aterosklerosis. *Contin Prof Dev.* 2017;44(9).
45. Jin N, Huang L, Hong J, et al. Elevated homocysteine levels in patients with heart failure: A systematic review and meta-analysis. *Medicine (Baltimore).* 2021;100(33).
46. Liu X, Dong T, Zhang Y, Zhao Y, Yang J, Gu C et al. Relationship between serum homocysteine level and cognitive impairment in patients with Parkinson's disease. *Pteridines.* 2019;30(1):177–82.
47. Amin HK, Sayed MK, Leheta OF. Homocysteine as a predictive biomarker in early diagnosis of renal failure susceptibility and prognostic diagnosis for end stages renal disease. 2016;38:1267–75
48. Long, Y, Nie, J. Homocysteine in Renal Injury. *Kidney Dis.* 2016;2:80–7.
49. Sriram K, Manzanares W, Joseph K. Thiamine in Nutrition Therapy. *Nutr Clin Pract.* 2012;27(1):41–50.
50. Frank LL. Thiamin in Clinical Practice. *J Parenter Enter Nutr.* 2015;39(5):503–20.
51. Costantini A, Pala MI, Compagnoni L, Colangeli M. High-dose thiamine as initial treatment for Parkinson's disease. *BMJ Case Rep.* 2013

52. Syarif A, Estuningtyas A, Setiawati A, Muchtar A, Arif A, Bahry B et al. *Farmakologi dan Terapi*. 5th ed. Jakarta; Balai Penerbit FK UI. 2007
53. Sugandhi VV, Pangen R, Vora LK, et al. Pharmacokinetics of vitamin dosage forms: A complete overview. *Food Science & Nutrition*. 2024;12(1):48-83.
54. Stach K, Stach W, Augoff K. Vitamin B6 in health and disease. *Nutrients*. 2021;1–11.
55. Abosamak NR, Gupta V. Vitamin B6 (pyridoxine). *Statpearls*. 2023
56. Clase CM, Ki V, Holden RM. Water-Soluble vitamins in people with low glomerular filtration rate or on dialysis: A Review. *Semin Dial*. 2013;26(5):546–67.
57. Elgar K. Vitamin B12: a review of clinical use and efficacy. *Nutri Med J*. 2022;1(3):9–25
58. Azzini E, Raguzzini A, Polito A. A brief review on vitamin b12 deficiency looking at some case study reports in adults. *Int J Mol Sci*. 2021;22(18):9694.
59. Modak K, John MJ. PB2548: comparison between weekly intravenous versus daily oral vitamin B12 supplementation in anemia with vitamin B12 deficiency. *HemaSphere*. 2023;7
60. Vasavada A, Sanghavi DK. Cyanocobalamin. *Statpearls*. 2023
61. Allen LH. Bioavailability of vitamin B12. *Int j vitam nutr res*. 2010;80:330-5.
62. Kobayashi S. Cardiovascular events in hemodialysis patients: challenging against vascular calcification. *Ann Vasc Dis* 2017;10(1):1–7.
63. Martella BM, Veiga GR, Alves BC, Azzalis LA, Junqueira VB, Gehrkei FS, et al. The importance of homocysteine levels in the prognosis of patients with

- chronic renal disease and in hemodialysis patients. *J Bras Patol Med Lab.* 2018;54(3):170–6
64. Capelli I, Cianciolo G, Gasperoni L, Zappulo F, Tondolo F, Cappuccilli M, et al. Folic Acid and Vitamin B12 Administration in PGK, Why Not?. *Nutrients.* 2019:1–20
65. Saka Y, Naruse T, Kato A, Tawada N, Noda Y, Mimura T et al. Thiamine status in end-stage chronic kidney disease patients: a single-center study. *Int Urol Nephrol.* 2018;50(10):1913–8.
66. Lu R, Fang Y, Zhou Y, Che M, Shen J, Liu Q et al. A pilot study of thiamin and folic acid in hemodialysis patients with cognitive impairment. *Ren Fail.* 2021;43(1):766–73
67. Tayebi A, Biniiaz V, Savari S, Ebadi A, Sjermeh MS, Einollahi B, et al . Effect of Vitamin B 12 supplementation on serum homocysteine in patients undergoing hemodialysis: A randomized controlled trial. *Saudi J Kidney Dis Transpl* 2016;27(2):256–262.
68. Aghsaeifard Z, Zendehtel A, Alizadeh R, Salehnasab A. Chronic hemodialysis: Evaluation of dialysis adequacy and mortality. *Annals of Medicine & Surgery.* 2022;76.
69. Chiu YW, Chang JM, Hwang SJ, Tsai JC, Chen HC. Pharmacological dose of vitamin B12 Is as effective as low-dose folinic acid in correcting hyperhomocysteinemia of hemodialysis patients. *Renal Failure.* 2009;31(4):278–83.
70. Ghanbari Y, Ahmed Munshi MU, Nagaraju K. Effect of folic acid, pyridoxine and cyanocobalamin in reducing the elevated level of homocysteine in advance

chronic kidney disease and end-stage renal disease. *Int Res J Pharm.* 2016;7(5):24-8.

71. Harris RC, Zhang MZ. The role of gender disparities in kidney injury. *Ann Transl Med.* 2020;8(7):514.
72. Ricardo AC, Yang W, Sha D, Appel LJ, Chen J, Wood MK, et al. Sex-related disparities in CKD progression. *JASN.* 2019;30(1):137-46.
73. Zaman SB, Hossain N, Rahman M. Associations between Body Mass Index and Chronic Kidney Disease in Type 2 Diabetes Mellitus Patients: Findings from the Northeast of Thailand. *Diabetes Metab J.* 2018;42(4):330
74. Utami AS, Asmara IGY, Irawati D. Hubungan Adekuasi Hemodialisis dengan Status Gizi Pasien Penyakit Ginjal Kronis yang Menjalani Hemodialisis Reguler di RSUD Kota Mataram. *JKunram.* 2021.
75. Prasad R, Jha RK, Keerti A. Chronic Kidney Disease: Its Relationship With Obesity. *Cureus.* 2022
76. Vayá A, Rivera L, Hernández-Mijares A, Fuente M, Sola E, Romagnoli M, et al. Homocysteine levels in morbidly obese patients. Its association with waist circumference and insulin resistance. *Clinical Hemorheology and Microcirculation.* 2012;52(1):49-56
77. Wang J, You D, Wang H, Yang Y, Zhang D, Lv J, et al. Association between homocysteine and obesity: A meta-analysis. *J Evidence Based Medicine.* 2021;14(3):208-17
78. Agarwal R. Blood pressure and mortality among hemodialysis patients. *Hypertension.* 2010;55(3):762-768.

79. Cherif AB, Bennouar S, Louafi A, Bouamra A, Temmar M, Bouafia M. Prevalence and control of hypertension in hemodialysis patients using ambulatory blood pressure in the area of Blida (Algeria). *Archives of Cardiovascular Diseases Supplements*. 2019;11(3).
80. MacRae C, Mercer SW, Guthrie B, Henderson D. Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in Scottish primary care. *Br J Gen Pract*. 2021;71(704):243-9.
81. Zemplényi A, Sággy E, Kónyi A, Szabó L, Wittmann I, Laczy B. Prevalence, Cardiometabolic Comorbidities and Reporting of Chronic Kidney Disease; A Hungarian Cohort Analysis. *Int J Public Health*. 2023;68.
82. Barman Z, Hasan M, Miah R, Miah R, Mou AD, Hafsa JM, et al. Association between hyperuricemia and chronic kidney disease: a cross-sectional study in Bangladeshi adults. *BMC Endocr Disord*. 2023;23(1):45
83. Hawthorne G, Lightfoot CJ, Smith AC, Khunti K, Wilkinson TJ. Multimorbidity prevalence and patterns in chronic kidney disease: findings from an observational multicentre UK cohort study. *Int Urol Nephrol*. 2023;55(8):2047-57.
84. Burnier M, Damianaki A. Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease. *Circulation Research*. 2023;132(8):1050-63.
85. Nordheim E, Geir Jenssen T. Chronic kidney disease in patients with diabetes mellitus. *Endocrine Connections*. 2021;10(5):151-9.
86. Astuti AT, Septriana. Asupan energi, zat gizi makro, dan zat gizi mikro pada pasien hemodialisis di RSUD Panembahan Senopati Bantul. *Nutrisia*. 2018;20(2):45-52.

87. Casla AC, Avesani CM, Beridze G, Ortola R, Esquinas EG, Garcia EL, et al. Protein Intake and Mortality in Older Adults With Chronic Kidney Disease. *JAMA Netw Open*. 2024;7(8).
88. Sahathevan S, Khor BH, Ng HM, Gafor AHA, Daud ZZ, Mafra D, et al. Understanding Development of Malnutrition in Hemodialysis Patients: A Narrative Review. *Nutrients*. 2020;12(10):3147.
89. Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero JJ, Chan W, et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. *American Journal of Kidney Diseases*. 2020;76(3):1-107
90. Hasibuan SF, Makmun A, Sukesu L. Profile of anemia and the relationship between hemoglobin levels and quality of life in end-stage chronic kidney disease patients undergoing chronic hemodialysis at Hasan Sadikin Hospital 2021-2022. *Inakidney*. 2025;1(1):17-23
91. Kovesdy CP, Davis JR, Duling I, Little DJ. Prevalence of anaemia in adults with chronic kidney disease in a representative sample of the United States population: analysis of the 1999–2018 National Health and Nutrition Examination Survey. *Clinical Kidney Journal*. 2023;16(2):303-11.
92. Bishaw F, Belay Woldemariam M, Mekonen G, Birhanu B, Abebe A. Prevalence of anemia and its predictors among patients with chronic kidney disease admitted to a teaching hospital in Ethiopia: A hospital-based cross-sectional study. *Medicine*. 2023;102(6)
93. Stosovic M, Stanojevic M, Ogrizovic SS, Jovanovic D, Djukanovic L. Relation between serum urea and mortality of hemodialysis patients. *Renal failure*. 2009;31:335-40

94. Putra RN, Perangin-angin VA, Ferdinand S, Tandanu E. Description of serum urea and creatinine levels pre hemodialysis and post hemodialysis at Royal Prima Hospital in chronic kidney disease. *AMCR*. 2021;2(2):118-22
95. Kilonzo SB, Rudovick L, Makambay P, Meremo A. Prevalence and predictors of hemodialysis inadequacy among patients on maintenance hemodialysis in Mwanza, Tanzania. *Ojneph*. 2023;13:91-103.
96. Boz G, Uludag K. Serum albumin trends in relation with prognosis of individuals receiving hemodialysis therapy. *Cureus*. 2021;13(11).
97. Kaye AD, Jeha GM, Pham AD, Fuller MC, Lerner ZI, Sibley GT, et al. Folic acid supplementation in patients with elevated homocysteine levels. *Adv Ther*. 2020;37(10):4149-64.
98. Drake VJ. Vitamin B6. *Linus Pauling Institute, micronutrient information center*. 2024
99. Deminice R, Portari GV, Marchini JS, Vannucchi H, Jordao AA. Effects of a low-protein diet on plasma amino acid and homocysteine levels and oxidative status in rats. *Ann Nutr Metab*. 2009;54:202-7
100. Wu CC, Zheng CM, Lin YF, Lo L, Liao MT, Lu KC. Role of homocysteine in end-stage renal disease. *Clinical Biochemistry*. 2012;45(16-17):1286-94.
101. Heinz J, Domröse U, Westphal S, Luley C, Neumann KH, Dierkes J. Washout of water-soluble vitamins and of homocysteine during haemodialysis: Effect of high-flux and low-flux dialyser membranes. *Nephrology*. 2008;13(5):384-9.
102. Ma F, Li Q, Zhou X, Zhao J, Song A, Li W, et al. Effects of folic acid supplementation on cognitive function and A β -related biomarkers in mild

- cognitive impairment: a randomized controlled trial. *Eur J Nutr.* 2019;58(1):345-56.
103. Kwok T, Wu Y, Lee J, Lee R, Yung CY, Choi G, et al. A randomized placebo- controlled trial of using B vitamins to prevent cognitive decline in older mild cognitive impairment patients. *Clinical Nutrition.* 2020;39(8):2399-405.
104. Bhargava S, Ali A, Bhargava EK, Manocha A, Kankra M, Das S, et al. Lowering homocysteine and modifying nutritional status with folic acid and vitamin B12 in Indian patients of vascular disease. *J Clin Biochem Nutr.* 2012;50(3):222-6.
105. Lee JA, Kim DH, Yu SJ, Oh DJ, Yu SH. Association of serum albumin and homocysteine levels and cardio-ankle vascular index in patient with continuous ambulatory peritoneal dialysis. *The Korean Journal Of Internal Medicine.* 2006;21(1):33-8.
106. Yadav V, Prakash V, Bushra F, Sinha M. Study of serum homocysteine level in patients with chronic kidney disease and its association with renal function and serum albumin. *Int J Res Med Sci.* 2020;8(6):2195-8
107. Rasi A, Zamanian A, Mehran G, Ezati A, Rastin V, Karimi S. Comparing the Effect of Injectable Vitamin B With Conventional Oral Treatment on Aphthous Stomatitis. *J Skin Stem Cell.* 2017
108. Wang H, Li L, Qin LL, Song Y, Vidal-Alaball J, Liu TH. Oral vitamin B₁₂ versus intramuscular vitamin B₁₂ for vitamin B₁₂

deficiency. Cochrane Metabolic and Endocrine Disorders Group, ed. Cochrane Database of Systematic Reviews. 2018;2018(3).

